Chemomab Therapeutics to Merge with Precision Medicine Pioneer Scipher Medicine
CMMB has more than doubled off its 52-week low of $1.35 on elevated volume (4.0× avg).
Summary
Chemomab Therapeutics has announced a definitive merger agreement with Scipher Medicine Corporation, following a 6-K filing just minutes prior. This significant corporate action is expected to be a transformative event for Chemomab, redefining its future operations and market position. The combined company plans to advance Nebokitug, a first-in-class anti-CCL24 antibody, through an AI-powered Phase 2 trial in rheumatoid arthritis, leveraging precision medicine approaches.
At the time of this announcement, CMMB was trading at $3.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.9M. The 52-week trading range was $1.35 to $4.92. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.